AB1399 INVESTIGATING THE USE OF VERTEBRAL HEIGHT MORPHOMETRY DATA AS A PREDICTOR OF FRACTURE: AN OBSERVATIONAL COHORT STUDY

Background Dual energy x-ray absorptiometry (DEXA) has an established place in the diagnosis of osteoporosis and fracture risk estimation using FRAX® tool. DEXA is also useful producing morphometry data on bones including vertebrae at low radiation doses during appointments. Currently there exists limited clinical use for vertebral height measurement, with no published as a measurement. FRAX currently uses bone mineral density from hip to calculate either or major osteoporotic fracture, however, previous literature identified that BMD predictor specific but not sensitive [1]. Moreover, it may be possible get such value certain patient demographics patients replacements. Therefore, further predictors fractures are needed better allow estimation. Objectives The aims this study assess measured routine appointments observational cohort. Methods We analysed 31546 referred district scanner northwest England between 2004-2019. Data collected attendance include site fragility lumbar L1-L4. Logistic models reporting odds ratio were used examine predictive L1-L4 different types fracture. Results mean age time first scan was 65 +/- 12.9 (SD). Our dataset comprised 26,156 (82.9%) female 5390 (17.1%) male patients. A total 11875 occurred our population. L1 3.117 (95% CI 3.117-3.12), L2: 3.239 3.236-3.242), L3:3.78 CI:3.75-3.381) L4: 3.424 CI: 3.420-3.428). Patients average these spinal levels less likely experience any type Interestingly when running analysis individually each site, associated sites. had highest while L2 least. Table 1. Conclusion This analyse data. found level protective however While link been known some consequently integrated into tool FRAX®, predict novel. Further research compare power well understanding role future iterations tools. Reference [1]El Miedany Y. FRAX: re-adjust re-think. Arch Osteoporos. 2020 Sep 28;15(1):150. doi: 10.1007/s11657-020-00827-z. PMID: 32989561; PMCID: PMC7522068. Acknowledgements: NIL. Disclosure Interests Hamzah amin: None declared, Marwan Bukhari Speakers bureau: sponsored attend regional, national international meetings by UCB celltech, Roche/Chugai, Pfizer, Abbvie, Merck, Mennarini, Janssen, Bristol-Myers Squib, Novartis Eli-lilly He received honoraria speaking attended advisory boards Sanofi-aventis, Eli-Lilly, Amgen, Gilead. educational groups revalidaid TREG consultants., Aqib Khan: declared.